Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
37,171,432
-
Share change
-
+3,117,602
-
Total reported value
-
$727,253,818
-
Price per share
-
$19.55
-
Number of holders
-
91
-
Value change
-
+$62,067,302
-
Number of buys
-
47
-
Number of sells
-
44
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q3 2020
As of 30 Sep 2020,
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) was held by
91 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
37,171,432 shares.
The largest 10 holders included
FMR LLC, RTW INVESTMENTS, LP, FARALLON CAPITAL MANAGEMENT LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., BlackRock Inc., Johnson & Johnson Innovation - JJDC, Inc., BVF INC/IL, Consonance Capital Management LP, BAKER BROS. ADVISORS LP, and VANGUARD GROUP INC.
This page lists
91
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.